Neuren Pharmaceuticals Limited has released a press release.
Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025
Earlier from Neuren Pharmaceuticals
- DAYBUE STIX now broadly available in US for Rett syndrome
- Acadia confirms plan to request CHMP re-examination
- 2025 royalty income A$65m, profit after tax A$30m
- Appendix 4E and 2025 full year accounts